(Total Views: 560)
Posted On: 02/14/2022 12:00:41 PM
Post# of 155189
Nice review of chemokine signaling in cancer, including our favorite, CCR5:
https://www.mdpi.com/1422-0067/21/20/7619/htm
https://www.mdpi.com/1422-0067/21/21/8412/htm
It is complicated:
A recent study showed that blocking CCR4 in a dog model of metastatic prostate cancer blocks T-Reg migration into the tumor microenvironment. I wonder if blocking CCR4 or CCR5 would be better for that?
https://jitc.bmj.com/content/10/2/e003731.long
https://www.mdpi.com/1422-0067/21/20/7619/htm
https://www.mdpi.com/1422-0067/21/21/8412/htm
Quote:
The role of chemokines in cancer has been the subject matter of a considerable number of papers. PubMed (https://pubmed.ncbi.nlm.nih.gov/) includes almost 22 thousand articles containing the words “chemokine” and “cancer” (title + abstract + keywords).
It is complicated:
Quote:
CCL5 is responsible for the infiltration of a tumor by NK cells [48,49,52,53], conventional type 1 dendritic cells [54], T helper cell type 1 (Th1) [28], and type 1 cytotoxic cells (Tc1) [22]. For this reason, some postulate that cancer therapies should combine immunotherapy with increasing the expression of CCL5 in the tumor to enhance the infiltration of the tumor by various immune cells [30,49,50].
On the other hand, CCL5 has also several pro-cancer properties (Figure 2). Its expression is elevated in breast cancer [60], glioblastoma multiforme [61], and hepatocellular carcinoma [62]. In a tumor, CCL5 expression is found in cancer cells [63,64], cancer-associated fibroblasts (CAF) [65], mesenchymal stem cells (MSC) [66], MDSC [67], TAM [68,69,70,71], and TIL [72].
A recent study showed that blocking CCR4 in a dog model of metastatic prostate cancer blocks T-Reg migration into the tumor microenvironment. I wonder if blocking CCR4 or CCR5 would be better for that?
https://jitc.bmj.com/content/10/2/e003731.long
(6)
(0)
